Status:
COMPLETED
Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures
Lead Sponsor:
Upsher-Smith Laboratories
Conditions:
Epilepsy
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to examine the safety of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Have completed the maintenance period of the P09-004 study.
- Continue to be treated with a stable dose of 1 to a maximum of 3 approved concomitant AEDs.
Exclusion
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT01191086
Start Date
October 1 2010
End Date
May 1 2014
Last Update
February 23 2015
Active Locations (68)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States
2
Ventura, California, United States
3
Gainsville, Florida, United States
4
Gulf Breeze, Florida, United States